Status and phase
Conditions
Treatments
About
This is a Phase 1, single-arm, open-label, dose-escalation and dose-expansion study. The main purpose is to evaluate the safety and tolerability, efficacy of CNCT19 CAR T-cell therapy in patients with autoimmune hemolytic anemia after failure of three or more lines of therapy. Participants will receive CNCT19 cell infusion after preconditioning, and they will receive a 1-year follow-up.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
6 participants in 1 patient group
Loading...
Central trial contact
Jingyu Zhao, MPH; Jun Shi, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal